acquisition– tag –

Strategic Review: Investing in Marketed Products and Next-Gen Modalities Astellas Pharma has executed a series of acquisitions and collaborations from 2015 to 2025 focused on immuno-oncology, ophthalmology, neurology, and gene therapy. K...

Strategic Review: From Cystic Fibrosis to Gene Editing and Regenerative Medicine Vertex Pharmaceuticals has leveraged its dominance in cystic fibrosis (CF) treatment to expand into gene editing, regenerative medicine, pain management, an...

Strategic Review: From Biologics to Rare Diseases, Oncology, and RNA Innovation Over the past decade, Amgen has expanded beyond its legacy focus on bone and inflammatory diseases to invest heavily in oncology, RNA therapies, and rare dis...

Strategic Review: From Blockbusters to Nuclear Medicine, Gene and Cell Therapy Over the past decade, Novartis has strategically shifted its focus toward high-value therapies, including nuclear medicine (Pluvicto), gene therapy (Zolgensma...

Strategic Overview: Dominance in Diabetes and Obesity with Oncology Expansion Eli Lilly has strengthened its global leadership in diabetes and obesity while expanding into oncology, neuroscience, and gene therapy. With the blockbuster su...

Strategic Review: Focused Expansion in Vaccines and Specialty Medicines Over the past decade, GSK has shifted from large-scale M&A to focused investments and strategic partnerships, particularly in vaccines, oncology, respiratory, an...

Strategic Review: Investing in ADCs, Rare Diseases, and Biomanufacturing Capabilities AstraZeneca has expanded significantly in oncology through antibody and ADC partnerships, including a high-profile collaboration with Japan’s Daiichi S...

Strategic Review: Beyond Keytruda—Pivot to Next-Gen Modalities Merck (MSD in the U.S.) built a strong oncology franchise with Keytruda. As patents expire, Merck is investing in ADCs, RNA therapies, cell therapy, and precision immunology ...

Strategic Review: From mRNA Success to Diversification in Rare Diseases, ADCs, and RNA Editing Pfizer strengthened its biopharmaceutical base with the acquisition of Hospira and GSK’s vaccine assets in 2015, followed by a major expansion...